How to Check Kwick Forensic Solutions IPO Allotment Status

Kwick Forensic Solutions Limited, incorporated in March 2005, provides products, solutions and technologies across forensic science, fingerprint science, cyber and digital forensics, DNA forensics, social-media analytics, big-data analytics and evidence management. Its solutions are primarily used by law-enforcement agencies and forensic investigation organisations.  

The company initially operated in software development, including 3D rendering, animation and simulation, before expanding into forensic science and training technologies. From FY2015 onwards, it began providing end-to-end forensic products and solutions focused on crime-scene investigation and total evidence management.  

Its portfolio includes fingerprint and evidence-collection kits, handheld forensic devices, laboratory equipment, mobile crime-scene investigation vehicles, cyber and digital forensic tools and DNA forensic solutions. 

Don’t Miss Out on the Next Big IPO – Invest With Just a Few Clicks!

Open Account Now

Kwick Forensic Solutions IPO is a ₹50.77 crore book-built BSE SME issue, comprising a fresh issue of approximately ₹41.05 crore and an offer for sale of approximately ₹9.72 crore. The total offer comprises about 56.42 lakh equity shares.  

The IPO opened for subscription on August 27, 2026 and closed on August 31, 2026. The basis of allotment is scheduled for September 1, 2026, followed by refunds and credit of shares on September 2. The shares are scheduled to list on BSE SME on September 3, 2026.  

The price band was fixed at ₹85 to ₹90 per share, with a lot size of 1,600 shares. Individual Investors are required to apply for at least two lots or 3,200 shares, translating into a minimum investment of ₹2,88,000 at the upper price band. Corporate CapitalVentures Private Limited is the book-running lead manager, while Bigshare Services Private Limited is the registrar.  

Registrar:  Bigshare Services Private Limited

BSE: BSE IPO Allotment Status Page 

Kwick Forensic Solutions IPO Subscription Status

Kwick Forensic Solutions IPO was subscribed 287.16 times on August 31, 2026, based on the final subscription data provided. The issue witnessed substantial demand across all three investor categories, with NIIs recording the highest subscription. The same 287.16-times overall figure and category-wise figures are reported by 5paisa's post-close subscription update.

The Individual Investor category was subscribed 311.78 times, after rising from 13.17 times on Day 1 to 36.23 times on Day 2.  

The QIB category witnessed a sharp increase in demand on the closing day, reaching 220.81 times subscription after recording no subscription during the first two days.  

Overall subscription increased from 7.51 times on Day 1 to 20.67 times on Day 2, before jumping to 287.16 times on Day 3. It is worth noting that some post-close exchange-based trackers subsequently displayed different final figures—such as 272.50 times overall—likely reflecting differences in data snapshots or classification. The table above retains the final figures provided and reported by 5paisa.  

Kwick Forensic Solutions IPO Share Price and Investment Details 

Kwick Forensic Solutions IPO price band was fixed at ₹85 to ₹90 per share, with a bid lot of 1,600 shares. Individual Investors are required to apply for at least 3,200 shares, or two lots, translating into a minimum investment of ₹2,88,000 at the upper price of ₹90.  

The IPO has a total issue size of approximately ₹50.77 crore, comprising a fresh issue of about ₹41.05 crore and an offer for sale of approximately ₹9.72 crore. The issue is proposed to list on the BSE SME platform.  

Based on the subscription figures provided, NIIs led demand at 317.87 times, followed by Individual Investors at 311.78 times and QIBs at 220.81 times, taking the overall subscription to 287.16 times.  

Given the level of oversubscription across investor categories, competition for allotment is high. The basis of allotment is scheduled for September 1, 2026, followed by refunds and credit of shares on September 2 and the proposed listing on September 3.  

Utilisation of IPO Proceeds 

Kwick Forensic Solutions proposes to utilise ₹31.42 crore from the fresh issue proceeds towards funding its working-capital requirements. This represents the primary identified use of funds from the fresh issue.  

The company's business involves supplying specialised forensic kits, equipment and integrated solutions, including projects secured through tenders. This can require maintaining inventory and funding procurement, fabrication and integration costs before customer payments are received.  

The remaining eligible fresh issue proceeds are proposed to be utilised towards general corporate purposes, subject to the limits specified in the offer documents.  

Since the IPO also includes an offer for sale of approximately ₹9.72 crore, Kwick Forensic Solutions will not receive the proceeds attributable to shares sold by the existing selling shareholders.  

Business Overview 

Kwick Forensic Solutions operates in the specialised forensic technology and law-enforcement solutions sector, providing products and technologies used in crime-scene investigation, evidence collection, fingerprint examination, cybercrime investigation, DNA forensics and digital evidence management.  

Its offering spans physical forensic products as well as technology-led solutions. These include fingerprint and evidence-collection kits, laboratory equipment, handheld forensic devices, mobile crime-scene investigation vehicles, cyber and digital forensic tools and DNA forensic solutions.  

The company's focus on Total Evidence Management enables it to participate across different stages of forensic investigation, from collection and preservation of physical evidence to digital investigation, analysis and evidence-management solutions.  

Kwick Forensic Solutions reported total income of ₹105.80 crore in FY26, compared with ₹65.08 crore in FY25 and ₹30.26 crore in FY24. Profit after tax increased to ₹13.51 crore in FY26, from ₹8.56 crore in FY25 and ₹2.83 crore in FY24.  

EBITDA stood at approximately ₹19.07 crore in FY26, compared with ₹12.25 crore in FY25 and ₹5.45 crore in FY24. The company also reported interest expense of ₹0.37 crore in FY26, compared with ₹0.67 crore in FY25.  

Key strengths include its specialised forensic product portfolio, presence across physical and digital forensics, end-to-end evidence-management capabilities, experience in the forensic solutions industry and exposure to growing requirements for technology-led investigation and law-enforcement infrastructure. 

Investors should also consider risks associated with dependence on government and institutional tenders, lengthy receivable and working-capital cycles, delays in order execution or payments, reliance on specialised technology and equipment, regulatory requirements, competition and the need to continually upgrade products as forensic and cyber-investigation technologies evolve. The company's trade receivables stood at around ₹22.88 crore as of March 31, 2026, highlighting the working-capital requirements of its business model.